Data / Form D filings / Ayala Pharmaceuticals, Inc.
Ayala Pharmaceuticals, Inc.: Form D filings
Ayala Pharmaceuticals, Inc., a biotechnology company in Monmouth Junction, NJ, filed 14 Form D notices with the SEC between 2009 and 2023. The latest, on November 2, 2023, reports $433,825 sold of a $433,825 offering to 3 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 9 DEER PARK DRIVE, SUITE K-1, Monmouth Junction, NJ, 08852
- Phone
- (732) 545-1590
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1100397
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Nov 2, 2023 | New notice | $433,825 | $433,825 | 3 | Oct 18, 2023 | sec.gov | |
| Feb 11, 2022 | New notice | $4,750,000 | $4,750,000 | 6 | Jan 31, 2022 | sec.gov | |
| Apr 28, 2021 | New notice | $11,093,521 | $11,093,521 | 2 | Apr 14, 2021 | sec.gov | |
| Dec 13, 2012 | New notice | $10,000,000 | $0 | $10,000,000 | 1 | Nov 13, 2012 | sec.gov |
| Jun 6, 2012 | New notice | Indefinite | $715,000 | 8 | May 18, 2012 | sec.gov | |
| May 29, 2012 | New notice | Indefinite | $4,473,673 | 29 | May 14, 2012 | sec.gov | |
| Feb 24, 2012 | New notice | Indefinite | $1,047,500 | 12 | Jan 9, 2012 | sec.gov | |
| Nov 15, 2011 | New notice | Indefinite | $1,977,500 | 12 | Oct 31, 2011 | sec.gov | |
| May 27, 2011 | New notice | Indefinite | $6,016,250 | 24 | May 12, 2011 | sec.gov | |
| Nov 15, 2010 | New notice | Indefinite | $835,000 | 10 | Nov 1, 2010 | sec.gov | |
| Jul 30, 2010 | New notice | $7,500,000 | $7,500,000 | 1 | Jul 19, 2010 | sec.gov | |
| Oct 22, 2009 | New notice | Indefinite | $50,000 | 1 | Oct 7, 2009 | sec.gov | |
| Oct 5, 2009 | New notice | $5,000,000 | $5,000,000 | 1 | Sep 24, 2009 | sec.gov | |
| Oct 1, 2009 | New notice | Indefinite | $961,650 | 7 | Jun 17, 2009 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Andres A. Gutierrez | Executive Officer | |
| Igor A. Gitelman | Executive Officer | |
| Pini A. Orbach | Director | |
| Murray A. Goldberg | Director | |
| Vered A. Bisker-Leib | Director | |
| Yuval A. Cabilly | Director | |
| Bridget A. Martell | Director | |
| Roy A. Golan | Executive Officer | |
| Robert A. Spiegel | Director | |
| David A. Sidransky | Director | |
| Roni A. Appel | Director | |
| Ken A. Berlin | Director, Executive Officer |
Other biotechnology companies in New Jersey that filed recently
- Ensho Therapeutics, Inc. $7.3 million · Oct 15, 2026
- Xenon Ophthalmics Inc $3.3 million · Oct 6, 2026
- LISATA THERAPEUTICS, INC. $351.9 million · Oct 2, 2026
- Bullseye Biodevices, Inc. $1.3 million · Aug 10, 2026
- Hepion Pharmaceuticals, Inc. $3.1 million · Aug 5, 2026
Every Form D from the week of Oct 30, 2023 · All recent filings in New Jersey · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Ayala Pharmaceuticals, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.